Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitors. These agents are used to improve lipid levels with a goal of CV risk reduction. Statins dominate the treatment paradigm owing to their good risk-benefit profile, evidence of CV benefits, and the availability of low-cost generic products. We expect recent positive cardiovascular outcomes trial (CVOT) data from certain nonstatin therapies, such as PCSK9 inhibitors and Vascepa, to influence the market penetration of these branded agents. Furthermore, the launches of novel therapies, including Novartis’s inclisiran and Esperion Therapeutics’ Nexletol / Nilemdo, will provide greater competition and drive market growth.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.